Literature DB >> 184810

BCG treatment of malignant pleural effusions in the rat.

M V Pimm, D G Hopper, R W Baldwin.   

Abstract

Intrapleurally injected cells of an ascitic rat tumour produced intrapleural effusions and solid pleural deposits. BCG, or its methanol extraction residue (MER) injected into the pleural space, suppressed tumour development and prolonged survival. Treatment was effective if given a few days before or after tumour injection. In contrast, active specific immunotherapy by repeated s.c. injection of viable or radiation-attenuated tumour cells in admixture with BCG was unsuccessful, and did not improve the response to intrapleural BCG treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184810      PMCID: PMC2025260          DOI: 10.1038/bjc.1976.179

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Vaccination against tuberculosis with nonliving vaccines. 3. Vaccination of guinea pigs with fractions of phenol-killed tubercle bacilli.

Authors:  D W WEISS; A Q WELLS
Journal:  Am Rev Respir Dis       Date:  1960-09

2.  Quantitative studies on cell-mediated immunity in the pleural cavity of guinea-pigs.

Authors:  S Yamamoto; C J Dunn; F Capasso; D A Deporter; D A Willoughby
Journal:  J Pathol       Date:  1975-10       Impact factor: 7.996

3.  BCG therapy of pleural and peritoneal growth of transplanted rat tumours.

Authors:  M V Pimm; R W Baldwin
Journal:  Int J Cancer       Date:  1975-02-15       Impact factor: 7.396

4.  BCG immunotherapy of rat tumours in athymic nude mice.

Authors:  M V Pimm; R W Baldwin
Journal:  Nature       Date:  1975-03-06       Impact factor: 49.962

Review 5.  BCG and cancer (first of two parts).

Authors:  R C Bast; B Zbar; T Borsos; H J Rapp
Journal:  N Engl J Med       Date:  1974-06-20       Impact factor: 91.245

6.  Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy.

Authors:  G L Bartlett; B Zbar
Journal:  J Natl Cancer Inst       Date:  1972-06       Impact factor: 13.506

7.  Tumour inhibition mediated by BCG in immunosuppressed rats.

Authors:  M Moore; N Lawrence; N W Nisbet
Journal:  Int J Cancer       Date:  1975-06-15       Impact factor: 7.396

8.  Methanol extraction residue of BCG in the treatment of transplanted rat tumours.

Authors:  D G Hopper; M V Pimm; R W Baldwin
Journal:  Br J Cancer       Date:  1975-02       Impact factor: 7.640

9.  Influence of whole body irradiation on bcg contact suppression of a rat sarcoma and tumour-specific immunity.

Authors:  M V Pimm; R W Baldwin
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640

10.  Serum antibody responses to an ascitic variant of rat hepatoma D23.

Authors:  R A Robins
Journal:  Br J Cancer       Date:  1975-07       Impact factor: 7.640

View more
  5 in total

1.  Malignant pleural effusion: further translational research is crucial.

Authors:  Yasuhiko Nishioka
Journal:  Transl Lung Cancer Res       Date:  2012-09

2.  Histopathology of BCG and thiotepa treated bladders.

Authors:  P Guinan; M Shaw; V Ray
Journal:  Urol Res       Date:  1986

Review 3.  Manipulation of host resistance in cancer therapy.

Authors:  R W Baldwin
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Tuberculous peritonitis developing in a case of documented peritoneal carcinomatosis.

Authors:  M Markman
Journal:  West J Med       Date:  1985-07

Review 5.  Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting.

Authors:  R W Baldwin; M V Pimm
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.